Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Seven patients ingested (2.5 mg/kg) daily dapsone. Their serum samples were analyzed daily during the first week by spectrophotometry for methaemoglobinemia and weekly blood samples for red blood cells, reticulocytes count and haptoglobin level. The acetylator phenotype of each patient was estimated on the capacity to acetylate isoniazid. Methaemoglobinemia was always observed within the 48 hours after drug intake. The dapsone induced anemia was moderate being maximum between day 25 and 40 after the beginning of treatment. Reticulocytemia appeared in the second week and haptoglobin levels decreased between day 5 and 8 of therapy in 5 patients and at day 15 for the two others. The seven patients are divided in 4 rapid acetylator and 3 slow acetylator. The acetylator phenotype was not correlated with methaemoglobin, haptoglobin levels or RBC counts.
Download full-text PDF |
Source |
---|
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!